Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 Veracyte, Inc ... data demonstrating the ability of the company,s molecular ... from other interstitial lung diseases (ILDs) using samples ... potential to help thousands of patients avoid invasive, ... IPF diagnosis – a frequent challenge for physicians ...
(Date:5/20/2015)... This year has been one of the harshest ... Pearl’s Premium Ultra Low Maintenance Lawn Seed comes to ... coming out of record bad weather. Offering new ... concerns related to water, health, and climate change, Pearl's ... the standard, water-wasting, chemical-treated standard lawn. Many homeowners ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
(Date:5/20/2015)... DENVER , May 20, 2015  Health ... connecting short-staffed healthcare organizations with job seekers looking ... SHIFT , a new mobile and online tool ... the healthcare industry. SHIFT enables employers ... locum tenens, travel nursing, per diem and other ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... and you haven,t backed up your holiday photos is a step ... into a new kind of computer memory. , Physicists at ... have made new advances in researching a new kind of memory, ... information on home computers. , Your hard drive ...
... companies align to leverage technologies for PACS data disaster ... Management (IKM) business unit of Siemens Healthcare ... and Harris Corporation ( www.harris.com ... providers affordable solutions critical for Picture Archiving and Communication ...
... April 3 Verenium Corporation (Nasdaq: ... high-performance specialty enzymes and next-generation cellulosic ethanol, today ... demonstration-scale facility in Jennings, Louisiana, and the recent ... Verenium is now consolidating its research and development ...
Cached Biology Technology:Beating the back-up blues 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 3Siemens Healthcare Announces Planned Collaboration with Harris Corporation 4Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... a consortium of 98 Ph.D.-granting universities, has selected Holly ... of Delaware,s College of Earth, Ocean, and Environment, to ... The competitive award, which provides $5,000 from ORAU ... university, is intended to enrich the research and educational ...
... scientists discovered a defect in cellular pathways that provides a ... in newborns, known as craniosynostosis. Mutations of the ... events that regulate bone formation at the stem cell level, ... journal Science Signaling . "Our work contributes to ...
... O157:H7 is present but rare in some wildlife species of ... to as the nation,s "salad bowl," reports a team or ... who are nearing completion of a massive field study to ... near Central Coast farms, presented their findings today during the ...
Cached Biology News:University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 2University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 3Stem-cell disruption induces skull deformity, UR study shows 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 3
... CultureWell cell culture chambered coverslips ... cells for staining and imaging. ... silicone gaskets with standard optical-quality ... and ready to use. Preassembled ...
Vybrant® Multidrug Resistance Assay Kit...
... mL - 25 mL pipets ,Angled acrylic pipet ... standard square or round pipet cans. Constructed of 6 ... 76 mm W x 76 mm H x 289 ... Overall dimensions: 89 mm W x 406 mm H ...
...
Biology Products: